Clinical trials: Psoriasis Vulgaris
Moderate to Severe Plaque-type Psoriasis
Secukinumab Dosage Optimisation in Partial Responders With Moderate to Severe Plaque-type Psoriasis
This study is designed to support the optimal use of secukinumab by providing data to refine guidance on dosing flexibility in patients with psoriasis.
- Trial name
- GAIN (NCT02474069)
- Testing
- Secukinumab
- Where
- 89 sites in Germany
- Volunteers
- 772 people
- Sponsor
- Novartis Pharmaceuticals
Moderate to Severe Chronic Plaque-type Psoriasis
Study to Assess the Long-term Safety, Tolerability, Efficacy of Secukinumab in Pediatric Patients of Age 6 to <18 Years, With Moderate to Severe Plaque Psoriasis
This was an open-label, parallel-group, two-arm, multicenter study in pediatric subjects aged 6 years to less than 18 years, at randomization, with moderate to severe chronic plaque psoriasis.
- Trial name
- NCT03668613
- Testing
- secukinumab low dose, secukinumab high dose
- Where
- 23 sites in United States, Belgium and 7 more
- Volunteers
- 84 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis Vulgaris
Pre-Post Multimodal Assessment Of Severe Psoriasis Vulgaris Using Clinical, Dermoscopic And QoL Measures
The goal of this observational study is to learn about the comprehensive changes in severe plaque psoriasis (Psoriasis Vulgaris) in adult participants undergoing standard treatment.
- Trial name
- NCT07495657
- Volunteers
- 45 people
- Sponsor
- Assiut University
Keloid, Alopecia Areata
Pain Outcomes Following Intralesional Corticosteroid Injections
Corticosteroid therapy, including intralesional and topical applications, has many indications within the fields of Dermatology, Plastic Surgery, and Orthopedics.
- Conditions
- Keloid, Alopecia Areata, Acne, Hypertrophic Scar
- Trial name
- NCT03630198
- Testing
- Corticosteroid with lidocaine, Corticosteroid with normal saline
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Atopic Dermatitis, Psoriasis Vulgaris
Blue Light in the Treatment of Inflammatory Skin Diseases
The goal of this clinical trial is to assess the effectiveness of full-body blue light irradiations in the treatment of inflammatory skin diseases (atopic dermatitis, psoriasis, eczema) and chronic pruritus in adult and pediatric…
- Conditions
- Atopic Dermatitis, Psoriasis Vulgaris, Eczema, Pruritus
- Trial name
- NCT06516783
- Testing
- Full Body Blue GEN 1.0 device
- Where
- Poland
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Medical University of Lodz
Psoriasis Vulgaris
An International, Multi-centre, Prospective, Non-controlled, Open, Single-group, 8-week Trial in Adolescent Subjects
An international, multi-centre, prospective, non-controlled, open, single-group, 8-week trial in adolescent subjects (aged 12 to 16 years, 11 months) with scalp and body psoriasis.
- Trial name
- NCT02038569
- Testing
- LEO 80185 gel
- Where
- 35 sites in United States, Canada and 5 more
- Volunteers
- 125 people
- Sponsor
- LEO Pharma
Psoriasis Vulgaris
Safety and Efficacy of Once Daily Topical Treatment With LEO 90100 Aerosol Foam in Adolescent Subjects With Plaque Psoriasis
An international, multi-centre, prospective, open-label, non-controlled, single-group, 4-week trial in adolescent subjects with plaque psoriasis.
- Trial name
- NCT02387853
- Testing
- LEO 90100
- Where
- 9 sites in United States, Netherlands and 2 more
- Volunteers
- 117 people
- Sponsor
- LEO Pharma
Chronic Dermatological Conditions, Eczema
A Randomised Controlled Trial of ePROM-Guided Flexible Scheduling in Dermatology
The goal of this clinical trial is to evaluate whether an electronic patient-reported outcome measure (ePROM)-guided flexible scheduling system can improve outpatient clinic resource utilisation in patients attending dermatology…
- Conditions
- Chronic Dermatological Conditions, Eczema, Urticaria, Psoriasis
- Trial name
- NCT07481019
- Testing
- Flexible ePROM-guided Scheduling System, electronic patient reported outcome measures (ePROMs)
- Volunteers
- 250 people
- Sponsor
- National University Hospital, Singapore
Psoriasis Vulgaris, Psoriasis Arthropathica
Infliximab Biosimilar for Intravenous Drip Infusion 100 mg "Pfizer" Drug Use Investigation (Psoriasis)
To collect information on the safety and effectiveness of Infliximab BS for Intravenous Drip Infusion 100 mg "Pfizer" against psoriasis vulgaris, psoriasis arthropathica, pustular psoriasis, or erythrodermic psoriasis under…
- Conditions
- Psoriasis Vulgaris, Psoriasis Arthropathica, Pustular Psoriasis, Erythrodermic Psoriasis
- Trial name
- NCT03885089
- Testing
- Infliximab [infliximab biosimilar 3]
- Where
- Japan
- Volunteers
- 10 people
- Sponsor
- Pfizer
Psoriasis Vulgaris
Glucose Trnsporter and PEDF in Psoriasis
Psoriasis is a chronic relapsing cutaneous immune mediated inflammatory disease(IMID). In which there are skin lesions characterized by erythema, thickness and scale formation with different size from a pinhead to 20 cm in…
- Trial name
- NCT04242082
- Testing
- GLUT 1 gene expression
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Assiut University
Psoriasis Vulgaris
Narrowband UVB Light Therapy to Patients With Dark Skin Types Who Have 10% of Their Body Involved With Psoriasis Vulgaris.
This study offers narrowband UVB light therapy to patients with both light and dark skin types who have 10% of their body involved with psoriasis vulgaris.
- Trial name
- NCT00220025
- Testing
- Phototherapy
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Mary Sullivan-Whalen
Psoriasis Vulgaris, Psoriatic Arthritis
Special Drug Use-results Survey to Evaluate Safety and Efficacy of Cosentyx in Pediatric Patients With PsV, PsA, or GPP
This was a multicenter, centrally registered observational study without a control group. This observational study was a specified drug use-results survey conducted under GPSP to collect information on safety and efficacy during…
- Conditions
- Psoriasis Vulgaris, Psoriatic Arthritis, Pustular Psoriasis
- Trial name
- NCT05215561
- Testing
- Cosentyx
- Where
- 21 sites in Japan
- Volunteers
- 36 people
- Sponsor
- Novartis Pharmaceuticals
Pruritus, Psoriasis Vulgaris
Safety, Efficacy, and Tolerability of SNA-120 in Subjects With Pruritus Associated With Psoriasis Vulgaris
To characterize the efficacy, safety and tolerability of SNA-120 at 2 doses versus placebo when administered topically for the treatment of pruritus associated with psoriasis vulgaris (PV) and PV itself.
- Trial name
- NCT03322137
- Testing
- SNA-120, Vehicle
- Where
- 38 sites in United States
- Volunteers
- 208 people
- Sponsor
- Sienna Biopharmaceuticals
Psoriasis Vulgaris
Formulation and Clinical Evaluation of Ethosomal and Liposomal Preparations of Anthralin in Psoriasis
Psoriasis is a common immune mediated inflammatory skin disease characterized by red heavily scaled plaques. Anthralin (1,8-dihydroxy-9-anthrone) which was introduced over 80 years ago has shown excellent efficacy in the…
- Trial name
- NCT03348462
- Testing
- ethosomal preparation of anthralin, liposomal preparation of anthralin
- Where
- Egypt
- Volunteers
- 20 people
- Sponsor
- Assiut University
Psoriasis Vulgaris
Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris
The purpose of this study is to evaluate the safety and efficacy of 4 weeks of TACLONEX ointment in adolescent patients with psoriasis vulgaris.
- Trial name
- NCT00817219
- Testing
- Calcipotriene plus betamethasone dipropionate ointment
- Where
- 8 sites in United States
- Volunteers
- 33 people
- Sponsor
- LEO Pharma
Psoriasis Vulgaris
Informative Value of Determining the Level of NF-κB Translocation in Lymphocyte Populations in Children With Psoriasis
This study is the first to quantify the level of NF-kB translocation in lymphocyte populations in children and adolescents with psoriasis of varying severity.
- Trial name
- NCT04989296
- Testing
- Peripheral blood samples were obtained following the standard procedures.
- Where
- Russia
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- National Medical Research Center for Children's Health, Russian Federation
Psoriasis
Post-Marketing Surveillance Study of OTEZLA
To evaluate the safety and efficacy of OTEZLA in actual clinical settings of use in patients with Psoriasis vulgaris that is with an inadequate response to topical therapies and Psoriasis arthropathica 1.
- Trial name
- NCT03284879
- Where
- Japan
- Volunteers
- 1,086 people
- Sponsor
- Amgen
Psoriasis Vulgaris
A Study Comparing LEO 80190 Ointment With Hydrocortisone Ointment, Both Applied Once Daily in the Treatment of Psoriasis Vulgaris on the Face and Intertriginous Areas
An international, multi-centre, prospective, randomised, double-blind, active-controlled, 2-arm, parallel group, 8-week, phase 3 clinical study in paediatric patients (aged 6 to 17 years) with psoriasis vulgaris on the face and…
- Trial name
- NCT01007591
- Testing
- LEO 80190, Hydrocortisone
- Where
- France
- Volunteers
- 40 people
- Sponsor
- LEO Pharma
Psoriasis Vulgaris, UVB Phototherapy Burn
Effect Narrow-Band UVB Radiations
Narrow-band UVR affects Interleukin 17 which has a major role in the pathogenesis of psoriasis Vulgaris. the aim of this study to evaluate the serum levels of Interleukin 17 in psoriatic patients and compare with the levels in…
- Trial name
- UVB (NCT05647187)
- Testing
- Serum Interleukin 17 levels, NB-UVB
- Where
- Egypt
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- South Valley University
Psoriasis Vulgaris
A Maximal Use Trial Evaluating the Pharmacokinetic Profile of MC2-01 Cream in Adolescent Subjects
This is a phase 2, open-label, single-group, multicentre trial in which the investigational product, MC2-01 cream, is investigated in adolescent subjects (age 12 to 16 years, 11 months) with clinically diagnosed extensive…
- Trial name
- NCT03819218
- Testing
- MC2-01 cream
- Where
- 2 sites in Czechia, Germany
- Volunteers
- 7 people
- Sponsor
- MC2 Therapeutics